

1st Annual MEETING ESAC

&

4th edition AI FOR ONCOLOGY and Cancer Research

May 7-8th, 2026, Milan

In Person & Online – RESIDENZIALE + FAD SINCRONA

ACCREDITAMENTO RESIDENZIALE:

ID ECM: RESIDENZIALE N. PROVIDER ECM: 1023
OBBIETTIVO FORMATIVO: 29- Innovazione tecnologica: valutazione, miglioramento dei processi di gestione delle tecnologie biomediche, chimiche, fisiche e dei dispositivi medici. Health Technology Assessment
NR. DISCENTI:
ORE FORMATIVE: 13
N. CREDITI: (residenziale)
ID AIFA: tba
EVENTO PLURISPONSOR

ACCREDITAMENTO FAD SINCRONA:

ID ECM: FAD N. PROVIDER ECM: 1023
OBBIETTIVO FORMATIVO: 29- Innovazione tecnologica: valutazione, miglioramento dei processi di gestione delle tecnologie biomediche, chimiche, fisiche e dei dispositivi medici. Health Technology Assessment
NR. DISCENTI:
ORE FORMATIVE: 13
N. CREDITI: (Fad)
EVENTO PLURISPONSOR

PROFESSIONI ALLE QUALI SI RIFERISCE L'EVENTO FORMATIVO SETTORIALE:

Professione	Discipline
FARMACISTA	FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE;
BIOLOGO	BIOLOGO;
MEDICO CHIRURGO	ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; ANGIOLOGIA; CARDIOLOGIA; DERMATOLOGIA E VENEREOLOGIA; EMATOLOGIA; ENDOCRINOLOGIA; GASTROENTEROLOGIA; GENETICA MEDICA; GERIATRIA; MALATTIE METABOLICHE E DIABETOLOGIA; MALATTIE DELL'APPARATO RESPIRATORIO; MALATTIE INFETTIVE; MEDICINA E CHIRURGIA DI ACCETTAZIONE E DI URGENZA; MEDICINA FISICA E RIABILITAZIONE; MEDICINA INTERNA; MEDICINA TERMALIA; MEDICINA AERONAUTICA E SPAZIALE; MEDICINA DELLO SPORT; NEFROLOGIA; NEONATOLOGIA; NEUROLOGIA; NEUROPSICHIATRIA INFANTILE; ONCOLOGIA; PEDIATRIA; PSICHIATRIA; RADIOTERAPIA; REUMATOLOGIA; CARDIOCHIRURGIA; CHIRURGIA GENERALE; CHIRURGIA MAXILLO-FACCIALE; CHIRURGIA PEDIATRICA; CHIRURGIA PLASTICA E RICOSTRUTTIVA; CHIRURGIA TORACICA; CHIRURGIA VASCOLARE; GINECOLOGIA E OSTETRICIA; NEUROCHIRURGIA; OFTALMOLOGIA; ORTOPEDIA E TRAUMATOLOGIA; OTORINOLARINGOIATRIA; UROLOGIA; ANATOMIA PATOLOGICA; ANESTESIA E RIANIMAZIONE; BIOCHIMICA CLINICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA; LABORATORIO DI GENETICA MEDICA; MEDICINA TRASFUSIONALE; MEDICINA LEGALE; MEDICINA NUCLEARE; MICROBIOLOGIA E VIROLOGIA; NEUROFISIOPATOLOGIA; NEURORADIOLOGIA; PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO-CLINICHE E MICROBIOLOGIA); RADIODIAGNOSTICA; IGIENE, EPIDEMIOLOGIA E SANITÀ PUBBLICA; IGIENE DEGLI ALIMENTI E DELLA NUTRIZIONE; MEDICINA DEL LAVORO E SICUREZZA DEGLI AMBIENTI DI LAVORO; MEDICINA GENERALE (MEDICI DI FAMIGLIA); CONTINUITÀ ASSISTENZIALE; PEDIATRIA (PEDIATRI DI LIBERA SCELTA); SCIENZA DELL'ALIMENTAZIONE E DIETETICA; DIREZIONE MEDICA DI PRESIDIO OSPEDALIERO; ORGANIZZAZIONE DEI SERVIZI SANITARI DI BASE; AUDIOLOGIA E FONIATRIA; PSICOTERAPIA; CURE PALLIATIVE; EPIDEMIOLOGIA; MEDICINA DI COMUNITÀ; MEDICINA SUBACQUEA E IPERBARICA;

INFERMIERE	INFERMIERE;
FISICO	FISICA SANITARIA
CHIMICO	CHIMICA ANALITICA

OVERVIEW

The AI for Oncology Conference aims to equip participants with a comprehensive understanding of how advanced AI technologies are transforming cancer care and research. As AI innovation accelerates, its applications in oncology are becoming essential across the spectrum of diagnosis, treatment, and research. From integrating diverse datasets, such as multiomics, imaging, and clinical data, to advancing diagnostic precision, AI is enabling the discovery of patterns that traditional methods often overlook.

Participants will explore how AI-driven platforms are improving the integration of data, leading to more accurate diagnostics and personalized treatment approaches for cancers such as lung, breast, and colorectal cancers. Innovations in radiomics and digital pathology will also be highlighted, showcasing how AI enhances the analysis of imaging data and histopathology, particularly for challenging cancers like pancreatic, liver prostate, and head and neck tumors.

The conference will further delve into the role of AI in optimizing clinical research, from designing clinical trials to refining targeted therapies and immunotherapies.

Case studies will illustrate how AI is driving advances in cancer care, including applications in melanoma, NSCLC, and ovarian cancers, where predictive algorithms can identify the best treatment regimens, from adaptive radiation therapy to chemotherapy or immunotherapy dosing. The integration of Large Language Models and Foundation Models offers new ways to analyze clinical data, providing real-time, evidence-based recommendations that assist oncologists in selecting the most effective therapies, whether hormonal treatments for breast cancer or targeted/immunotherapy drugs for NSCLC or unknown primary tumors.

Additionally, the conference will emphasize the need for collaboration across healthcare providers, researchers, and industry partners, underscoring how such partnerships enhance diagnostic accuracy and treatment delivery for various cancer types, including breast, lung, and gastrointestinal cancers. Ultimately, the conference will provide a platform for participants to gain insights into cutting-edge AI advancements and how they can be applied to improve cancer diagnosis, treatment, and patient outcomes across a range of cancer types.

The shared knowledge and diverse experiences will enable clinicians, researchers, and technologists to further develop and implement innovative AI solutions in oncology.

Format

The event will cover two days. The speakers will have a diverse background to reflect the spectrum of Artificial Intelligence research (and beyond), from Artificial Intelligence engineering experts, to clinicians and translational researchers, and hybrid figures such as clinical Artificial Intelligence specialists. Faculty members represent worldwide centers of excellence in the field. The attendance is expected to mirror this variety, along with participants with a more specific background in imaging and pathology.

The conference also includes poster sessions, with prizes for the best posters in various AI fields. Participants will also be encouraged to participate to a call for abstracts, with the opportunity to present their work in flash talks during the symposium.

SCIENTIFIC DIRECTORS

Arsela Prelaj,

Esac President

MD, PhD, Medical Oncologist, Thoracic Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori

Head Of Artificial Intelligence for Oncology Lab, Milano, Italy

Jakob Nikolas Kather,

Esac Elect-President

MD, MSc, Professor of Medicine and Computer Science TUD Dresden University of Technology Dresden, Germany

SCIENTIFIC COMMITTEE

Mihaela Aldea, Julien Calderaro, Mireia Crispin, Filippo de Braud, Helena Linardou, Claes Lundström, Vanja Miskovic, Alessandra Pedrocchi, Raquel Pérez-Lopez, Daniel Truhn, Loic Verlingue

SCIENTIFIC SECRETARIAT

Narmin Ghaffari Laleh

Giovanni Scoazec

CONGRESS VENUE

Politecnico di Milano

Trifoglio Building - Campus Leonardo

Via Bonardi, 9 - 20133 Milano

VIRTUAL CONFERENCE

web: <https://www.events-fad.com/>

adress: C/O EVENTS SRL Via Lotto 9 – 60019 Senigallia AN

GENERAL INFORMATION

Cme Provider and Organizing Agency:

Events SRL provider 1023

Via Lotto 9, 60019 Senigallia, Italy

Tel. +39 071 7930220 - Fax. +39 071 7938406

www.events-communication.com

segreteria@events-communication.com

OFFICIAL LANGUAGE:

The official language is English

REGISTRATIONS

Registrations fees:



EVENTS

CONGRESS&COMMUNICATION

Free for Esac Members www.esac-network.eu/register/

Non Members 150,00 Euro

You may register for IN-PERSON OR ONLINE-ONLY ACCESS

SCIENTIFIC PROGRAM

May 7th, 2026

08:00 Registrations open

08:30-09:30 POSTER SESSION

09:30 Welcome

Arsela Prelaj, Jakob Nikolas Kather

Giovanni Apolone, President OEI, Organisation of European Cancer Institutes

Paolo Corradini, Scientific Director, Fondazione IRCCS INT

Maria Teresa Montella, General Director, Fondazione IRCCS INT

Donatella Sciuto, Chancellor, PoliMi

Pietro Auletta, IPOP Onlus

Emanuele Monti, Presidente IX Commissione Permanente Sostenibilità Sociale, Casa e Famiglia Regione Lombardia

09:50 AI From patients perspective

Massimo Di Maio, President of AIOM

10:00 AI in Low and Middle income countries

Evis Sala, Minister of Health and Social Welfare of Albania

10:10 Introduction from ESAC steering committee

Mireia Crispin Ortuzar, Helena Linardou, Narmin Ghaffari Laleh

SESSION 1 plenary

FROM DATA TO INSIGHT: BUILDING RELIABLE FOUNDATIONS FOR AI IN CANCER

Chairs: **Iwona Lugowska, Claes Lundstrom**

10:10 Data- Bias at the source: understanding and mitigating data imbalances in NSCLC and immunotherapy

Vanja Miskovic

10:30 Small data, big trouble: rare cancer bias in AI training sets

Guillaume Jaume

10:45 Discussion

10:55 Technical challenges for implementation and interoperability

Jens Kleesiek

11:15 USE CASE - Lessons from the clinic: data quality pitfalls in AI-based early detection: breast cancer example

Francisco Sanchez-Vega



EVENTS

CONGRESS&COMMUNICATION

11:25 Discussion

11:35 *Coffee Break*

SESSION 2 plenary

LLMs AND COPILOTS FOR CANCER RESEARCH AND TREATMENT

Chairs: **Jakob Nikolas Kather, Arsela Prelaj**

11:55 LLMs in cancer research: real-world colorectal cancer examples
Isabella Wiest

12:15 KEYNOTE LECTURE - AI as medical copilot for treatment decision-making
Faisal Mahmood

12.55 Best Oral 1

13:05 Discussion

13:15 *Lunch Break*

SESSION 3 plenary

AGENTIC AI

Chairs: **Luca Agnelli, Mark Carman**

14:15 AI agents integration for tumor boards and IO treatment decision
Federica Corso

14:30 Multiagents for clinical trial matching and phase 1 pan-cancer treatment selection
Loic Verlingue

14:45 SOTA of AI agents in cancer research
Dyke Ferber

15:00 Discussion

PARALLEL - ROUND TABLES

SESSION 4A

CLINICAL IMPLEMENTATION OF AI IN ONCOLOGY

Chairs: **Julien Calderaro, Luca Boldrini**

15:20 AI-driven pathology in clinical practice: head and neck and other cancers example use case
Alexander Pearson

15:35 DL and risk stratification in radiology application: kidney and prostate cancer use case
Keno Bressemer

15:45 AI in image-guided interventions and surgical decision support in lung cancer disease
Nikolaos Koufos

- 15:55 AI applications in radiotherapy for oropharyngeal cancer and osteonecrosis
Laia Humbert
- 16:05 Deploying an AI tool in routine clinical workflow (barriers and breakthroughs)
Mihaela Aldea
- 16:15 Discussion
-

SESSION 4B TRUSTWORTHY AND RESPONSIBLE AI IN CANCER

Chairs: **Evangelia Christodoulou, Fabio Pagni**

- 15:20 Trust, transparency and accountability in oncology AI
Karim Lekadir
- 15:30 Evaluation process for generative AI
Jacqueline Lammert
- 15:40 Explainable AI for doctors: example in breast cancer
Luigi De Angelis
- 15:50 Best Oral 2
- 16:00 Navigating regulatory pathways for AI medical devices in Europe and beyond
Stephen Gilbert
- 16:15 Discussion
-

SESSION 4C TECHNOLOGY TRANSFER OF AI SOLUTIONS IN HEALTHCARE

Chairs: **Alberto Redaelli, Alessandra Turi**

- 15:20 Title TBD
Jorge Reis-Filho
- 15:35 Experiences from TEF Health (TBC)
Petra Ritter
- 15:50 Pathway to a patent for DL in colonoscopy
Elena De Momi
- 16:00 USE CASE 1
Mattias Rantalainen

- 16:10 USE CASE 2
Victor Savevski
- 16:20 Discussion
- 16:45 *Coffee Break*

PARALLEL SESSIONS NO CME

5A INDUSTRY SYMPOSIUM

Chairs: **Francesco Trovò, Laura Mazzeo**

17:00 TBC

5B MEET THE EXPERTS

Chairs: **Narmin Ghaari Laleh, Giovanni Scoazec**

17:00 3 faculty members for
informal discussions
(groups of 30, e.g.)
TBC

5C TECH SYMPOSIUM

Chairs: **TBD**

SPECIAL PLENARY

Chairs: **Nicola Fusco, Vincenzo L'Imperio**

- 18:00 What will the future look like?
Daniel Truhn
- 18:40 End of Conference Day 1
- 18:40 General Assembly Meeting ESAC

May 8th, 2026

08:30 POSTER SESSION
Participants will present their posters

Modrators: **Filippo Pesapane, Leonardo Provenzano**

09:50 AI pros and cons: promises versus bottlenecks
Debate: Marco Gustav, Marcello Restelli

SESSION 6 plenary ETHICS AND PATIENT-CENTERED RESEARCH

Chairs: **Helena Linardou, Alessandra Pedrocchi**

10:00 Patient autonomy, uncertainty human values, trust and distrust in an AI context
Delia Nicoara



EVENTS

CONGRESS&COMMUNICATION

- 10:15 AI in digital health, QoL and toxicity in pancancer patients treated with immunotherapy
Jarushka Naidoo
- 10:30 Balancing clinical utility and privacy concerns in data
Fidelia Cascini
- 10:45 How to design patient-centered, ethical clinical trials with AI: in immunotherapy and target therapies
Arsela Prelaj
- 11:00 Discussion
- 11:10 *Coffee Break*

PARALLEL SESSIONS

SESSION 7A

CLINICAL IMPLEMENTATION OF AI IN ONCOLOGY

Chairs: **SYNTHETIC DATA AND SYNTHETIC PATIENTS**

- 11:50 The promise of synthetic data: current evidence and limitations in the breast cancer setting
Oliver Diaz
- 12:05 Synthetic arms versus RWD arms versus control arms in trials
Debate: *Miriam Koopman, Rodrigo Dienstmann*
- 12:25 Multimodal synthetic data - how to generate images and omics in longitudinal fashion in breast and other cancers
Saverio D'Amico
- 12:40 Discussion

SESSION 7B

MULTIMODAL AND MULTI-AI

Chairs: **Antonio Marra, Raquel Perez-Lopez**

- 11:50 VLMs for treatment prediction in ovarian and kidney cancer
Zeyu Gao
- 12:05 Toward Clinically Deployable AI models: Safeguards Against Distribution Shifts
Jana Lipkova
- 12:20 LLMs for target and drug discovery: a personalized therapy for every single patient
Marina Garassino
- 12:40 Discussion



EVENTS

CONGRESS&COMMUNICATION

13:00 *Lunch Break*

SESSION 8 plenary

MULTIOMICS AND FOUNDATION MODELS

Chairs: **Mireia Crispin Ortuzar, Giuseppe Curigliano**

- 14:00 Foundation models for multiomics and spatial omics applications in hematological diseases
Sizun Jiang
- 14:20 Pan-cancer multiomics science: how and when in the research and the clinical settings
Sohrab Shah
- 14:40 Technical and implementation challenges of AI in multi-omics research: cancers of unknown primary example
Julien Vibert
- 14:20 Discussion

SESSION 9 plenary

CLOSING SESSION AND PRIZES

Chairs: **Robert Lugowski, Luca Invernizzi, Marco Masseroli**

- 15:00 Computational biology and digital twins in breast cancer
Cristina Curtis
- 15:40 Best oral or 'honorable mentions' from poster evaluation
- 15:50 Best oral or 'honorable mentions' from poster evaluation
- 16:00 Poster Prize and ESAC Awards
- 16:20 AI in 2040: the light and dark side
Jakob Nikolas Kather
- 16:30 GoodBye Words
Arsela Prelaj, Jakob Nikolas Kather, Presidents

FACULTY

Luca Agnelli, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Mihaela Aldea, Gustave Roussy, Villejuif, France
Luca Boldrini, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
Keno Bressem, Technical University Munich, Italy
Julien Calderaro, Henri Mondor Hospital, Créteil, France
Mark Carman, Politecnico di Milano DEIB, Milan, Italy
Fidelia Cascini, National Institute of Health, Rome, Italy
Evangelia Christodoulou, German Cancer Research Center DKFZ, Germany
Federica Corso, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Mireia Crispin Ortuzar, University of Cambridge, United Kingdom
Giuseppe Curigliano, IEO Istituto Europeo di Oncologia, Milan, Italy
Christina Curtis, Stanford University, USA
Saverio D'Amico, AI Center Humanitas Research Hospital, Milan
Massimo Di Maio, University of Turin and AOU Città della Salute e della Scienza, Turin, Italy
Luigi De Angelis, University of Pisa, Italy
Filippo De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Elena De Momi, Politecnico di Milano DEIB, Milan, Italy
Oliver Diaz, University of Barcelona, Spain
Rodrigo Dienstmann, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Dyke Ferber, Else Kröner Fresenius Center for Digital Health, Dresden, and National Center for Tumor Diseases, Heidelberg, Germany
Nicola Fusco, IEO Istituto Europeo di Oncologia, Milan, Italy
Zeyu Gao, University of Cambridge, United Kingdom
Marina Chiara Garassino, University of Chicago, USA
Narmin Ghaffari Laleh, TU Dresden and University Hospital of Heidelberg, Germany
Stephen Gilbert, Technische Universität Dresden, Germany
Marco Gustav, Else Kröner Fresenius Center for Digital Health, Dresden, and National Center for Tumor Diseases, Heidelberg, Germany
Laia Humbert Vidan, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Luca Invernizzi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Guillaume Jaume, Harvard Medical School, Brigham and Women's Hospital, Boston, USA
Sizun Jiang, Harvard Medical School/BIDMC, Boston, USA
Nicolas Jakob Kather, Technical University of Dresden, Germany
Jens Kleesiek, University Hospital Essen, Germany
Miriam Koopman, Utrecht University, The Netherlands
Nikolaos Koufos, Metropolitan Hospital of Athens, Greece
Jacqueline Lammert, TUM School of Medicine & Health, Munich, Germany
Karim Lekadir, University of Barcelona, Spain
Vincenzo L'imperio, University of Milano-Bicocca, Milan, Italy



EVENTS

CONGRESS&COMMUNICATION

Helena Linardou, Metropolitan Hospital of Athens, Greece
Jana Lipkova, University of California, Irvine, USA
Robert Lugowski, CEO and Co-Founder of CliniNote
Iwona Lugowska, Maria Sklodowska-Curie National Research Institute and Oncology Centre, Warsaw, Poland
Claes Lundstrom, Linköping University, Sweden
Faisal Mahmood, Harvard Medical School, Division of Medical Sciences, USA
Antonio Marra, IEO Istituto Europeo di Oncologia, Milan, Italy
Marco Masseroli, Politecnico di Milano DEIB, Milan, Italy
Laura Mazzeo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Vanja Mišković, Politecnico di Milano DEIB, Milan, Italy
Jarushka Naidoo, Beaumont Hospital Dublin and RCSI, Ireland
Delia Nicoara, Institutul Oncologic „Prof. Dr. Ion Chiricuță” Cluj-Napoca, Romania
Fabio Pagni, University of Milano-Bicocca, Milan, Italy
Alexander Pearson, University of Chicago, USA
Alessandra Pedrocchi, Politecnico di Milano DEIB, Milan, Italy
Raquel Pérez-Lopez, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Filippo Pesapane, IEO Istituto Europeo di Oncologia, Milan, Italy
Pietro Pinoli, Politecnico di Milano DEIB, Milan, Italy
Arsela Prelaj, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Leonardo Provenzano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Mattias Rantalainen, Karolinska Institutet, Stockholm, Sweden
Alberto Redaelli, Politecnico di Milano DEIB, Milan, Italy
Jorge Reis-Filho, Chief AI for Science Innovation, AstraZeneca, New York, USA
Marcello Restelli, Politecnico di Milano DEIB, Milan, Italy
Petra Ritter, Charité University Medicine Berlin and Berlin Institute of Health, Germany
Francisco Sanchez-Vega, Memorial Sloan Kettering Cancer Center, New York, USA
Evis Sala, Minister of Health and Social Welfare of Albania
Victor Savevski, Humanitas AI Center, Milan, Italy
Giovanni Scoazec, ESAC - European Interdisciplinary Society for AI in Cancer Research, Milan, Italy
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, USA
Alberto Traverso, Vita-Salute San Raffaele University, Milan, Italy
Francesco Trovò, Politecnico di Milano DEIB, Milan, Italy
Daniel Truhn, Aachen University Hospital, Germany
Alessandra Turi
Loïc Verlingue, Centre Léon Bérard, Lyon, France
Julien Vibert, University of Heidelberg, Germany
Isabella Wiest, Else Kröner Fresenius Center for Digital Health, Dresden, Germany